Fig. 7: Inhibition of V-ATPase abrogates HFD-induced weight re-gain in formerly obese mice.

a Schematic diagram of weight rebound mouse experiment. b Average daily food intake (t = 4.31, df = 26, p < 0.001) and c HFD-induced weight re-gain (n = 14/group; group: F = 18.29, df = 1, p = 0.002; time: F = 119, df = 10, p < 0.001; genotype X time: F = 13.78, df = 10, p < 0.001). d WAT as percentage of body weight (n = 8; t = 2.74, df = 14, p = 0.01). e Relative gene expression in hypothalamus as determined by qPCR (Agrp: t = 0.18, df = 12, p = 0.43; Npy: t = 1.53, df = 12, p = 0.15; Pomc: t = 2.27, df = 12, p = 0.04; Cart: t = 0.04, df = 12, p = 0.96). f Gdf15 gene levels in WAT (n = 7/group; t = 4.46, df = 12, p < 0.001) and plasma concentration (n = 6/group; t = 2.32, df = 10, p = 0.04). g Relative gene expression in WAT (Fasn: t = 3.93, df = 13, p = 0.001; Acaca: t = 2.58, df = 12, p = 0.02; Cpt1a: t = 2.73, df = 10, p = 0.02; Lep: t = 6.74, df = 13, p < 0.001; Adipoq: t = 0.21, df = 12, p = 0.84; Atf4: t = 2.86, df = 12, p = 0.02; Ddit3: t = 2.11, df = 13, p = 0.05). h Western blot and densinometric quantification of membrane-bound and cytoplasmic Atp6V1a and Atp6V0a1 in gonadal WAT (n = 3/group; MemV1: t = 19.18, df = 4, p < 0.001; MemV0: t = 2.22, df = 4, p = 0.04; CytoV1: t = 0.76, df = 4, p = 0.25; CytoV0: t = 0.43, df = 4, p = 0.34) of WT mice treated with either Veh (Blue) or BFM (white) during weight rebound (Rb). Data is expressed as mean ± SEM and * denotes statistical significance at p < 0.05. b, d–h were analyzed by student t-test (2 tailed), c was analyzed by repeated-measures two-way ANOVA followed by two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli with false discovery rate of 0.10.